Skip to content
The Intraday
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

AMRX Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

AMRX
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

AMRX Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

Amneal Pharmaceuticals, Inc.

AMRX
$17.10
$-0.78 (-4.36%)-4.36%
Closed
Loading chart...
IndexN/A
Market Cap5.46B
Enterprise Value6.37B
Income$0.01B
Sales$0.70B
EmployeesN/A
P/E19.00
P/S1.31
P/B-55.77
P/C14.63
EV/EBITDA10.56
EV/SalesN/A
EPS (ttm)0.90
EarningsN/A
Gross Margin37.63%
Oper. Margin14.02%
Profit Margin2.39%
Volume2.25M
Shs Outstand0.32B
Change-4.36%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$2.79B$2.39B$2.21B$2.09B$1.99B$1.63B$1.66B$1.03B
Cost of Revenue$1.77B$1.53B$1.42B$1.32B$1.36B$1.27B$946.59M$507.48M
Gross Profit$1.02B$863.87M$791.46M$768.97M$628.39M$353.00M$716.40M$526.18M
Gross Margin36.52%36.09%35.78%36.73%31.54%21.70%43.08%50.90%
Operating Expenses$771.11M$659.50M$886.39M$616.26M$537.24M$601.68M$736.08M$281.07M
Operating Income$249.33M$204.37M$-94.93M$152.72M$91.16M$-248.68M$-19.67M$245.10M
Operating Margin8.92%8.54%-4.29%7.29%4.57%-15.29%-1.18%23.71%
Net Income$-116.89M$-83.99M$-129.99M$10.62M$91.06M$-361.92M$-169.73M$167.65M
Net Margin-4.18%-3.51%-5.88%0.51%4.57%-22.25%-10.21%16.22%
EPS (Basic)$-0.38$-0.48$-0.86$0.07$0.62$-4.57$-1.33$1.46
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$3.50B$3.47B$3.80B$3.94B$4.01B$3.67B$4.35B$1.34B
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$3.55B$3.41B$3.59B$3.57B$3.65B$3.32B$3.46B$1.72B
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$-109.27M$19.78M$298.42M$360.34M$303.27M$232.01M$896.36M$-385.74M
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$-109.27M$19.78M$298.42M$360.34M$303.27M$232.01M$896.36M$-385.74M
Total Liabilities & Stockholders Equity$3.50B$3.47B$3.80B$3.94B$4.01B$3.67B$4.35B$1.34B
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$-116.89M$-83.99M$-129.99M$10.62M$91.06M$-361.92M$-169.73M$167.65M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$295.10M$345.58M$65.10M$241.82M$379.00M$1.71M$250.23M$234.19M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
Yesterday · 9:55AMAmneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Whyzacks.com ↗Aug 10 · 8:00AMAmneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leaderglobenewswire.com ↗Aug 7 · 1:01PMAmneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?zacks.com ↗Aug 1 · 3:57AMArkadios Wealth Advisors Takes Position in Amneal Pharmaceuticals, Inc. $AMRXdefenseworld.net ↗Jul 31 · 12:15PMAMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raisedzacks.com ↗Jul 30 · 2:23PMAmneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcriptseekingalpha.com ↗Jul 30 · 10:31AMCompared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metricszacks.com ↗Jul 30 · 10:06AMAmneal Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com ↗
Show 12 more stories↓
Jul 30 · 8:20AMAmneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimateszacks.com ↗Jul 30 · 6:00AMAmneal Reports Second Quarter 2026 Financial Resultsglobenewswire.com ↗Jul 23 · 1:27PMKaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firmbusinesswire.com ↗Jul 21 · 10:46AMHere's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stockzacks.com ↗Jul 17 · 8:00AMAmneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentationsglobenewswire.com ↗Jul 9 · 4:05PMAmneal to Report Second Quarter 2026 Results on July 30, 2026globenewswire.com ↗Jul 2 · 10:46AMHere's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stockzacks.com ↗Jun 29 · 3:00AMZambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuationsglobenewswire.com ↗Jun 24 · 10:50AMWhy Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Termzacks.com ↗Jun 17 · 12:30PMThe Healthcare M&A Waveforbes.com ↗Jun 11 · 10:17AMAMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?zacks.com ↗Jun 10 · 8:17PMIs Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvaluedgurufocus.com ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
BUCHI J KEVIN
Sell
168.6K
$17.31
$2.9M
Aug 11, 26
Nark Ted C
Sell
50.0K
$11.72
$586K
Nov 17, 25
Shah Nikita
Option
95.5K
$2.75
$263K
Nov 12, 25
Shah Nikita
Option
36.3K
$2.75
$100K
Nov 12, 25
Shah Nikita
Sell
131.9K
$11.92
$1.6M
Nov 12, 25

Company

CEO: Chirag K. PatelEmployees: 8700www.amneal.com
About the company↓

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Discover more

You may be interested in
NFLX

Netflix Inc

$74.79

↓ 1.97%
TSLA

Tesla Inc

$332.81

↑ 0.58%
MA

Mastercard Inc

$561.44

↓ 0.31%
JPM

JPMorgan Chase & Co

$362.04

↑ 0.63%
AMD

Advanced Micro Devices

$474.32

↑ 1.01%
NVDA

NVIDIA Corp

$217.50

↓ 0.02%
V

Visa Inc

$362.82

↑ 0.60%
PYPL

PayPal Holdings Inc

$59.00

↓ 0.12%
ADBE

Adobe Inc

$263.71

↓ 3.39%
ORCL

Oracle Corp

$145.44

↓ 3.71%
ABX

Abacus Global Management Inc

$8.92

↓ 6.30%
AMZN

Amazon.com Inc

$272.27

↓ 2.09%
The Intraday

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC